Cara Therapeutics, a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, released its inaugural Environmental, Social, and Governance (ESG) report highlighting the Company’s efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility.

The report's key highlights are:

Corporate governance: A cross-functional ESG Group has been established to monitor and enhance policy implementation, reporting periodically to the Board of Directors.

Workplace diversity: The Company is strengthening its diversity and inclusivity efforts with a gender-balanced leadership team and Board of Directors. Its employee base reflects the national labour force with 33% diversity and 58% female employees.

Environmental stewardship: The Company has taken initiatives to minimise its carbon footprint by adopting a paper-free work environment, developing energy efficiency policies, and reducing single-use plastics in the office.

Community service: The Company is dedicated to giving back to the communities where it operates and has introduced a fully paid Day of Service programme for employees to participate in charitable causes.

“Our first ESG report establishes a solid reporting baseline of the work underway at Cara Therapeutics that extends beyond our commitment to transforming the way chronic pruritus is treated and reflects our focus on innovating sustainability, operating responsibly, and empowering people,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “We look forward to providing an annual account of our ongoing ESG efforts and being transparent about our performance, progress, and challenges as we strive to make fundamental ESG issues a key consideration for how we do business.”

For more investor-related news

Source: Cara Therapeutics

Click here to read or download the report.